TTrialPathMatch Me to Trials
← Back to trials
RecruitingLow-grade GliomaAdvanced Solid Tumor

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Eligible age

0.5–25 yrs

Accepts

All genders

Locations

14 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.

Sponsor: Day One Biopharmaceuticals, Inc.

You may qualify if…

  • ✓ Low Grade Glioma \& Low-Grade Glioma Extension: a relapsed or progressive LGG with documented known activating BRAF alteration.
  • ✓ Advanced Solid Tumor: locally advanced or metastatic solid tumor with documented known or expected to be activating RAF fusion.
  • ✓ Participants must have histopathologic verification of malignancy at either original diagnosis or relapse.
  • ✓ Must have received at least one line of prior systemic therapy and have documented evidence of radiographic progression.
  • ✓ Must have at least 1 measurable lesion as defined by RANO (Arms 1 \& 2) or RECIST v1.1 (Arm 3) criteria

You may not qualify if…

  • ✕ Participant's tumor has additional previously-known activating molecular alterations.
  • ✕ Participant has symptoms of without radiographically recurrent or radiographically progressive disease.
  • ✕ Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testing or current diagnostic criteria.
  • ✕ Other inclusion/exclusion criteria as stipulated by protocol may apply

Where it's recruiting

California

San Francisco

District of Columbia

Washington D.C.

Illinois

Chicago

Maryland

Baltimore

Michigan

Ann Arbor

Missouri

St Louis

New York

New York

Oregon

Portland

Pennsylvania

Philadelphia

Texas

Houston

Source: ClinicalTrials.gov · NCT04775485 · last updated 2025-04-10